Last reviewed · How we verify
NCT03726853
The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497
Phase 2 trial testing CKD-497 200mg in Respiratory Infection in 220 participants. Completed in 21 March 2019.
21 March 2019
Quick facts
| Lead sponsor | Chong Kun Dang Pharmaceutical |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 29 May 2018 |
| Primary completion | 21 March 2019 |
| Estimated completion | 21 March 2019 |
| Sites | 15 locations across South Korea |
Drugs / interventions tested
- CKD-497 200mg — full drug profile →
- CKD-497 300mg — full drug profile →
- CKD-497 placebo — full drug profile →
- Comparator
- Comparator placebo
Conditions studied
- Respiratory Infection — all drugs for Respiratory Infection →
Sponsor
Chong Kun Dang Pharmaceutical — full company profile →
Who can join
Adults 19 to 75, any sex, with Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of CKD-497
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The safety and efficacy of CKD-497 in patients with acute upper respiratory tract infection and bronchitis symptoms: a multicenter, double-blind, double-dummy, randomized, controlled, phase II clinical trial.
Ra SW, Kim SY, Lim YY, Park SJ, et al · · 2021 · cited 2× · PMID 33569179 · DOI 10.21037/jtd-20-1567
Verify or expand the search:
- PubMed search for NCT03726853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Infection
Currently open trials in the same condition.
- NCT06390878 — Nationwide Research on the Rewilding of Kindergarten Yards · NA · recruiting
- NCT05860387 — Early Diagnosis of Invasive Lung Aspergillosis · recruiting
Other Chong Kun Dang Pharmaceutical trials
Trials by the same sponsor.
- NCT07404735 — A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 · Phase 1 · not yet recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
- NCT07258745 — Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-appro · Phase 1 · recruiting
- NCT07304726 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers · Phase 1 · completed
- NCT07304700 — Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03726853 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chong Kun Dang Pharmaceutical
- Last refreshed: 6 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03726853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing